A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects

• Published in: Drug design, development and therapy Vol. 9; no. default; pp. 729 - 736
• Main Authors: Park, Sang-In, Lee, Howard, Oh, Jaeseong, Lim, Kyoung Soo, Jang, In-Jin, Yu, Kyung-Sang, Jung, Jong Hyuk, Kim, Jeong-Ae
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2015; Taylor & Francis Ltd; Dove Press; Dove Medical Press
• Subjects: Adult; Antidiabetics; Area Under Curve; Chemistry, Pharmaceutical; Clinical medicine; Clinical trials; Comparative analysis; Confidence intervals; Controlled release; Controlled release technology; Cross-Over Studies; Delayed-Action Preparations; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); dipeptidyl peptidase 4; Dipeptidyl Peptidase 4 - blood; Dipeptidyl-peptidase IV; Dipeptidyl-Peptidase IV Inhibitors - administration & dosage; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; Dipeptidyl-Peptidase IV Inhibitors - blood; Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics; DPP-4 inhibitor; Drug Combinations; Drug dosages; Drug metabolism; Drug Therapy, Combination; Food; Formulations; Glucose; Healthy Volunteers; Hospitals; Humans; Hypoglycemic agents; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - blood; Hypoglycemic Agents - pharmacokinetics; Insulin resistance; Laboratories; Life sciences; Male; Mass spectrometry; Mass spectroscopy; Mathematical analysis; Metformin; Metformin - administration & dosage; Metformin - adverse effects; Metformin - blood; Metformin - pharmacokinetics; Middle Aged; Oral administration; Organization and Administration; Original Research; Patient outcomes; Peptidase; Pharmaceutical industry; Pharmacodynamics; Pharmacokinetics; Pharmacology; Pharmacology, Experimental; Piperidones - administration & dosage; Piperidones - adverse effects; Piperidones - blood; Piperidones - pharmacokinetics; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - blood; Pyrimidines - pharmacokinetics; Republic of Korea; Spectrophotometry; Sustained release; T2DM; Tablets; Testing; Therapeutic Equivalency; type 2 diabetes mellitus; Young Adult; Republic of Korea; South Korea; type 2 diabetes mellitus; T2DM; dipeptidyl peptidase 4; DPP-4 inhibitor
• ISSN: 1177-8881; 1177-8881
• DOI: 10.2147/DDDT.S75980

In type 2 diabetes mellitus, fixed-dose combination (FDC) can provide the complementary benefits of correction of multiple pathophysiologic defects such as dysfunctions in glycemic or metabolic control while improving compliance compared with separate tablets taken together. The objective of the stu...